Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Short Interest Update

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) was the target of a significant decrease in short interest during the month of January. As of January 30th, there was short interest totaling 225,376 shares, a decrease of 26.3% from the January 15th total of 305,750 shares. Approximately 9.2% of the company’s shares are short sold. Based on an average trading volume of 204,964 shares, the days-to-cover ratio is presently 1.1 days. Based on an average trading volume of 204,964 shares, the days-to-cover ratio is presently 1.1 days. Approximately 9.2% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on EKSO shares. Wall Street Zen upgraded shares of Ekso Bionics to a “hold” rating in a research note on Saturday, December 13th. HC Wainwright cut shares of Ekso Bionics from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 31st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Ekso Bionics in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Ekso Bionics currently has a consensus rating of “Hold” and an average price target of $10.50.

Ekso Bionics Stock Performance

Shares of EKSO stock opened at $9.87 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.66 and a quick ratio of 1.09. The firm has a 50-day moving average of $7.62 and a 200-day moving average of $5.47. Ekso Bionics has a one year low of $2.73 and a one year high of $12.70. The company has a market cap of $25.86 million, a P/E ratio of -1.74 and a beta of 0.80.

Hedge Funds Weigh In On Ekso Bionics

Several institutional investors have recently modified their holdings of the business. Consolidated Portfolio Review Corp purchased a new stake in shares of Ekso Bionics during the third quarter valued at approximately $333,000. Geode Capital Management LLC grew its stake in Ekso Bionics by 68.9% in the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after purchasing an additional 10,281 shares during the period. Citadel Advisors LLC purchased a new stake in shares of Ekso Bionics during the 3rd quarter valued at $198,000. Virtu Financial LLC purchased a new position in shares of Ekso Bionics in the 3rd quarter worth about $57,000. Finally, Shay Capital LLC bought a new position in Ekso Bionics during the third quarter valued at about $67,000. 6.42% of the stock is owned by institutional investors.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.